<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932967</url>
  </required_header>
  <id_info>
    <org_study_id>EMATO0321</org_study_id>
    <nct_id>NCT04932967</nct_id>
  </id_info>
  <brief_title>Use of nMoABs for the Treatment of COVID-19 in Patients With HM.</brief_title>
  <official_title>Use of Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Patients With Hematological Malignancies (SIE-GIMEMA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter retrospective, non-interventional observational study to evaluate the&#xD;
      efficacy of nMoAbs in HM patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter retrospective, non-interventional observational study. The&#xD;
      participating centres will retrospectively review all episodes of SARS-CoV-2 infection&#xD;
      occurring in HMs identified at their institutions from February 2020 to May 2021 and treated&#xD;
      with nMoAbs, to evaluate their efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time to SARS-nCov-2 test negativization</measure>
    <time_frame>3 months</time_frame>
    <description>To assess the efficacy of nMoAbs in infected HM patients compared to the historical control</description>
  </primary_outcome>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Covid19</condition>
  <condition>Hematological Malignancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients older than 18 years of age with HM who received&#xD;
        nMoAbs, approved by AIFA, for the treatment of SARS-CoV-2 infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must meet all the following criteria for study entry:&#xD;
&#xD;
               1. Age equal to or greater than 18 years of age.&#xD;
&#xD;
               2. Diagnosis of HM (acute leukemias, myelodysplastic syndromes, myeloproliferative&#xD;
                  neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any&#xD;
                  stage/status.&#xD;
&#xD;
               3. Third generation rapid molecular or antigen test positive for SARS-CoV-2 from&#xD;
                  February 2020 until May 2021&#xD;
&#xD;
               4. Treatment with anti SARS CoV 2 nMoAbs approved by AIFA&#xD;
&#xD;
               5. Not hospitalized for COVID-19 at the time of nMoAbs administration&#xD;
&#xD;
               6. Not on oxygen therapy at the time of nMoAbs administration&#xD;
&#xD;
               7. At least one of the following symptoms for no more than 10 days:&#xD;
&#xD;
                    -  Fever&#xD;
&#xD;
                    -  Cough&#xD;
&#xD;
                    -  Anosmia&#xD;
&#xD;
                    -  Ageusia / dysgeusia&#xD;
&#xD;
                    -  Pharyngodynia&#xD;
&#xD;
                    -  Asthenia&#xD;
&#xD;
                    -  Headache&#xD;
&#xD;
                    -  Nausea&#xD;
&#xD;
                    -  Diarrhea&#xD;
&#xD;
                    -  Myalgia&#xD;
&#xD;
                    -  Dyspnea&#xD;
&#xD;
                    -  Tachypnea&#xD;
&#xD;
               8. Signed written informed consent according to ICH/EU/GCP and national local laws&#xD;
                  (if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Hematological diseases, other than HM.&#xD;
&#xD;
             2. Not tested positive for SARS-CoV-2&#xD;
&#xD;
             3. Patients in disease remission &quot;off therapy&quot; for more than 6 months&#xD;
&#xD;
             4. Immune plasma treatment in the previous two months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aou &quot;San Giovanni Di Dio E Ruggi D'Aragona&quot; - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmine Selleri</last_name>
      <phone>3356166591</phone>
      <email>cselleri@unisa.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutralizing Monoclonal Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

